Page last updated: 2024-11-05

dichloroacetic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Dichloroacetic acid (DCA) is a colorless liquid with a pungent odor. It is a strong organic acid that is used in various industrial applications, including the synthesis of pharmaceuticals, pesticides, and dyes. DCA can be synthesized through the chlorination of acetic acid, though this process is challenging due to the formation of trichloroacetic acid as a byproduct. DCA has been researched for its potential therapeutic effects, specifically in cancer treatment, as it has been shown to inhibit the growth of various cancer cell lines. However, due to its toxicity and potential side effects, its clinical use is currently limited. Further research is ongoing to investigate DCA's potential applications in various medical fields.'

Cross-References

ID SourceID
PubMed CID6597
CHEMBL ID13960
CHEBI ID36386
SCHEMBL ID7777
MeSH IDM0006267

Synonyms (93)

Synonym
dichloressigsaeure
CHEBI:36386 ,
EN300-20014
HMS3393P22
2,2-dichloro-acetic acid
dichloroethanoic acid
acetic acid, dichloro-
wln: qvygg
nsc2654
dichloracetic acid
dichloroacetic acid ,
2,2-dichloroacetic acid
nsc-2654
dichlorethanoic acid
urner's liquid
MLS000028893
smr000059158
dichloro-acetic acid
TF4 ,
inchi=1/c2h2cl2o2/c3-1(4)2(5)6/h1h,(h,5,6
bichloracetic acid
acetic acid, dichloro- (8ci,9ci)
dca (acid)
dkhuk
NCGC00091444-01
MLS001424165
nsc 2654
un1764
ai3-18370
dichloroacetic acid (iupac)
ccris 4016
hsdb 6894
einecs 201-207-0
kyselina dichloroctova [czech]
brn 1098596
79-43-6
dichloroacetic acid, reagentplus(r), >=99%
dichloroacetic acid, analytical standard
MLS001074861
NCGC00091444-02
HMS2051P22
D0308
CHEMBL13960
NCGC00091444-04
NCGC00091444-03
AKOS005720869
LMFA01090070
NCGC00259912-01
tox21_202363
tox21_300419
NCGC00254261-01
BBL011449
tox21_111133
dtxsid2020428 ,
cas-79-43-6
dtxcid20428
HMS2232H11
CCG-101070
STL146561
unii-9lsh52s3lq
acetic acid, 2,2-dichloro-
9lsh52s3lq ,
dichloroacetic acid [un1764] [corrosive]
4-02-00-00498 (beilstein handbook reference)
kyselina dichloroctova
FT-0624700
dichloroacetic acid [hsdb]
dichloroacetic acid [iarc]
dichloroacetic acid [mi]
dichloroacetic acid [vandf]
dichloroacetic acid [who-dd]
dichloroacetic acid-d2
HMS3370D12
DB08809
NC00320
SCHEMBL7777
tox21_111133_1
NCGC00167845-02
un 1764
mfcd00004223
F2191-0226
dca deblock (0.36m dichloroacetic acid in toluene)
dichloroacetic acid, biotech. grade, >=98%
dichloroacetic acid, pestanal(r), analytical standard
dichloroacetic acid, puriss., 99%
dichloroacetic acid 1000 microg/ml in methyl-tert-butyl ether
dicloroacetic acid
dichloro acetic acid
AS-14228
Q412845
bdbm227588
2,2-dichloroaceticacid-1-13c
Z104476414

Research Excerpts

Overview

Dichloroacetic acid (DCA) is a liver carcinogen that induces DNA hypomethylation in mouse liver. It is also used therapeutically to treat a variety of metabolic disorders in humans.

ExcerptReferenceRelevance
"Dichloroacetic acid (DCA) is a major by-product of water disinfection by chlorination. "( Altered gene expression in mouse livers after dichloroacetic acid exposure.
Allen, JW; DeAngelo, AB; Fuscoe, JC; George, MH; Thai, SF, 2003
)
2.02
"Dichloroacetic acid (DCA) is a liver carcinogen that induces DNA hypomethylation in mouse liver. "( Prevention by methionine of dichloroacetic acid-induced liver cancer and DNA hypomethylation in mice.
Kramer, PM; Pereira, MA; Tao, L; Wang, W, 2004
)
2.06
"Dichloroacetic acid (DCA) is a drinking water contaminant, a therapeutic agent, and a rodent carcinogen. "( Glutathione transferase zeta-catalyzed bioactivation of dichloroacetic acid: reaction of glyoxylate with amino acid nucleophiles.
Anders, MW; Anderson, WB; Board, PG, 2004
)
2.01
"Dichloroacetic acid (DCA) is a compound found in chlorinated drinking water. "( Analysis of dichloroacetic acid in rat blood and tissues by hydrophilic interaction liquid chromatography with tandem mass spectrometry.
Bartlett, MG; Bruckner, JV; Delinsky, AD; Delinsky, DC; Fisher, JW; Muralidhara, S, 2005
)
2.15
"Dichloroacetic acid (DCAA) is a by-product of drinking water disinfection, is a known rodent hepatocarcinogen, and is also used therapeutically to treat a variety of metabolic disorders in humans. "( Effect of short-term drinking water exposure to dichloroacetate on its pharmacokinetics and oral bioavailability in human volunteers: a stable isotope study.
Schultz, IR; Shangraw, RE, 2006
)
1.78
"Dichloroacetic acid is a common disinfection by-product in surface waters and is a probable minor metabolite of trichloroethylene. "( Quantitative evaluation of dichloroacetic acid kinetics in human--a physiologically based pharmacokinetic modeling investigation.
Campbell, JL; Fisher, JW; Keys, DA; Li, T; Schultz, I, 2008
)
2.09
"Dichloroacetic acid (DCA) is a complete hepatocarcinogen and tumor promoter in the male B6C3F1 mouse. "( Biochemical, pathologic and morphometric alterations induced in male B6C3F1 mouse liver by short-term exposure to dichloroacetic acid.
Carter, HW; Carter, JH; DeAngelo, AB, 1995
)
1.94
"Dichloroacetic acid (DCA) is a chlorination byproduct found in finished drinking water. "( Assessment of the mutagenicity of dichloroacetic acid in lacI transgenic B6C3F1 mouse liver.
DeAngelo, AB; George, MH; Leavitt, SA; Ross, JA, 1997
)
2.02
"Dichloroacetic acid (DCA) is a common drinking-water contaminant, is hepatocarcinogenic in rats and mice, and is a therapeutic agent used clinically in the management of lactic acidosis. "( Glutathione transferase zeta-catalyzed biotransformation of dichloroacetic acid and other alpha-haloacids.
Anders, MW; Board, PG; Tong, Z, 1998
)
1.99
"Dichloroacetic acid (DCA) is a contaminant found in treated drinking water due to chlorination. "( Sensitive high-performance liquid chromatography method for the simultaneous determination of low levels of dichloroacetic acid and its metabolites in blood and urine.
Fisher, JW; Moghaddam, AP; Narayanan, L; Sudberry, GL; Taylor, AG, 1999
)
1.96
"Dichloroacetic acid (DCA) is a contaminant of chlorinated drinking water supplies, is carcinogenic in rats and mice, and is a therapeutic agent used for the treatment of congenital lactic acidosis. "( Inactivation of glutathione transferase zeta by dichloroacetic acid and other fluorine-lacking alpha-haloalkanoic acids.
Anders, MW; Anderson, WB; Board, PG; Gargano, B, 1999
)
2
"Dichloroacetic acid (DCA) is a major by-product of water disinfection by chlorination. "( Detection of early gene expression changes by differential display in the livers of mice exposed to dichloroacetic acid.
Allen, JW; DeAngelo, AB; Fuscoe, JC; George, MH; Thai, SF, 2001
)
1.97
"Dichloroacetic acid (DCA) is a principal by-product of the chlorine disinfection of water containing humic and fulvic acids, and is also a drug of interest in the therapeutic management of metabolic disorders. "( Developmental toxicity of dichloroacetate in the rat.
Randall, JL; Read, EJ; Smith, MK; Stober, JA, 1992
)
1.73
"Dichloroacetic acid (DCA) is a by-product of the chlorine disinfection of water and may occur in treated water at levels exceeding 100 micrograms/L. "( Cardiopathic effects of dichloroacetate in the fetal Long-Evans rat.
Christ, SA; Epstein, DL; Nolen, GA; Randall, JL; Read, EJ; Smith, MK; Stober, JA, 1992
)
1.73

Effects

Dichloroacetic acid (DCA) has potential for use in cancer therapy and the treatment of metabolic acidosis. CA has been shown to increase significantly the incidence of hepatic adenomas (HAs) and hepatocarcinomas (HCs) in mice.

ExcerptReferenceRelevance
"Dichloroacetic acid (DCA) has been shown to prevent cell death."( Combined Treatment of Dichloroacetic Acid and Pyruvate Increased Neuronal Survival after Seizure.
Choi, BY; Choi, HC; Hong, DK; Kang, BS; Kho, AR; Lee, SH; Park, MK; Song, HK; Suh, SW, 2022
)
1.76
"Dichloroacetic acid (DCA) has been used therapeutically to treat lactic acidosis and is potentially of use in cancer chemotherapy."( Phenylalanine-induced leucopenia in genetic and dichloroacetic acid generated deficiency of glutathione transferase Zeta.
Blackburn, AC; Board, PG; Cappello, J; Matthaei, K; Theodoratos, A; Tu, WJ, 2009
)
1.33
"Dichloroacetic acid (DCA) has potential for use in cancer therapy and the treatment of metabolic acidosis. "( Dichloroacetic acid up-regulates hepatic glutathione synthesis via the induction of glutamate-cysteine ligase.
Blackburn, AC; Board, PG; Cappello, J; Dahlstrom, JE; Theodoratos, A; Tummala, P, 2012
)
3.26
"Dichloroacetic acid (DCA) has recently been shown to increase significantly the incidence of hepatic adenomas (HAs) and hepatocarcinomas (HCs) in male B6C3F1 mice. "( The role of hyperplastic nodules in dichloroacetic acid-induced hepatocarcinogenesis in B6C3F1 male mice.
Daniel, FB; DeAngelo, AB; Potter, CL; Richmond, RE, 1991
)
2

Actions

ExcerptReferenceRelevance
"Dichloroacetic acid (DCA) can inhibit pyruvate dehydrogenase kinase (PDK)."( DCA Protects against Oxidation Injury Attributed to Cerebral Ischemia-Reperfusion by Regulating Glycolysis through PDK2-PDH-Nrf2 Axis.
Dai, Q; Huang, S; Li, R; Li, S; Mo, Y; Ni, X; Wang, J; Zhang, A; Zhao, X, 2021
)
1.34

Toxicity

ExcerptReferenceRelevance
" Chloroacetic acids are also metabolites of widely used and toxic halogenated hydrocarbons."( Ninety day toxicity study of chloroacetic acids in rats.
Ansari, GA; Bhat, HK; Campbell, GA; Kanz, MF, 1991
)
0.28
" The incidence of soft tissue malformations was dose related and was statistically significant at doses toxic to the dam (45 mg/kg)."( Developmental toxicity of dichloroacetonitrile: a by-product of drinking water disinfection.
Randall, JL; Read, EJ; Smith, MK; Stober, JA, 1989
)
0.28
"The metabolic and toxic effects of 2-chloropropionate and dichloroacetate, activators of the pyruvate dehydrogenase complex, were compared."( Comparison of the metabolic and toxic effects of 2-chloropropionate and dichloroacetate.
Felten, SY; Harris, RA; O'Connor, BL; Peterson, RG; Powell, RS; Yount, EA; Yum, MN, 1982
)
0.26
" In addition, each of the metabolites tested were significantly less developmental toxic than the parent compound, trichloroethylene."( Evaluation of the developmental toxicity of trichloroethylene and detoxification metabolites using Xenopus.
Bantle, JA; Fort, DJ; Hull, M; Rayburn, JR; Stover, EL, 1993
)
0.29
" Reaction of chlorine with naturally present organic compounds can result in toxic by-products."( In vivo genotoxicity of dichloroacetic acid: evaluation with the mouse peripheral blood micronucleus assay and the single cell gel assay.
Afshari, AJ; Allen, JW; DeAngelo, AB; Fuscoe, JC; George, MH; Salman, T; Tice, RR, 1996
)
0.6
" Elucidation of this mechanism in another animal model at a different phyletic level than rodents would advance the risk assessment process for government agencies concerned with regulation and provision of safe drinking water."( Hepatotoxicity of the drinking water disinfection by-product, dichloroacetic acid, in the medaka small fish model.
DeAngelo, AB; Lopez, L; McHugh Law, J, 1998
)
0.54
" The toxic effects of CFA, which is an excellent substrate but a poor inactivator of GSTZ1-1, have not been investigated."( Nephrotoxicity of chlorofluoroacetic acid in rats.
Anders, MW; Baggs, RB; Krenitsky, DM; Lantum, HB, 2002
)
0.31
"We present the effects and adverse effects of dichloroacetate (DCA) in a girl with mitochondrial disorder."( [Adverse effects of dichloroacetate in a girl with mitochondrial disorder].
Fukumizu, M; Hanaoka, S; Hirayama, Y; Izumi, M; Kaga, M; Murayama, K; Sasaki, M; Sugai, K, 2003
)
0.32
" We have previously shown that the haloacetic acids (HAs), dichloro (DCA), dibromo (DBA) and bromochloro (BCA) acetic acid are developmentally toxic in mouse whole embryo culture."( Developmental toxicity of mixtures: the water disinfection by-products dichloro-, dibromo- and bromochloro acetic acid in rat embryo culture.
Andrews, JE; Hunter, ES; Klinefelter, GR; Mole, LM; Nichols, HP; Schmid, JE, 2004
)
0.32
"Dichloroacetate (DCA) is one of the toxic by products that are formed during the chlorine disinfection process of drinking water."( Dichloroacetate-induced developmental toxicity and production of reactive oxygen species in zebrafish embryos.
Hassoun, E; Kariya, C; Williams, FE, 2005
)
0.33
" Fluoride is one of many methoxyflurane metabolites and may itself cause toxicity and/or reflect formation of other toxic metabolite(s)."( New insights into the mechanism of methoxyflurane nephrotoxicity and implications for anesthetic development (part 2): Identification of nephrotoxic metabolites.
Ensign, D; Kharasch, ED; Liggitt, HD; Schroeder, JL; Whittington, D, 2006
)
0.33
" Because their co-formation is unique to methoxyflurane compared with other volatile anesthetics and they are more toxic than fluoride alone, this suggests a new hypothesis of methoxyflurane nephrotoxicity."( New insights into the mechanism of methoxyflurane nephrotoxicity and implications for anesthetic development (part 2): Identification of nephrotoxic metabolites.
Ensign, D; Kharasch, ED; Liggitt, HD; Schroeder, JL; Whittington, D, 2006
)
0.33
" However, recent clinical trials indicate that adults are considerably more susceptible to this adverse effect than children."( Age-dependent kinetics and metabolism of dichloroacetate: possible relevance to toxicity.
Dixit, V; Guo, X; James, MO; Liu, HP; Shroads, AL; Stacpoole, PW, 2008
)
0.35
" Involvement of p66shc in adverse effects of these drugs was determined in p66shc knockdown, Ser36 phosphorylation (S36A) and cytochrome c-binding (W134F)- deficient cells."( The role of p66shc in taxol- and dichloroacetic acid-dependent renal toxicity.
Arany, I; Clark, JS; Ember, I; Juncos, LA; Reed, D; Szabó, I, 2013
)
0.67
" Knockdown of p66shc, mutation of its Ser36 (S36A) or cytochrome c binding site (W134F) attenuated adverse effects of the two drugs."( The role of p66shc in taxol- and dichloroacetic acid-dependent renal toxicity.
Arany, I; Clark, JS; Ember, I; Juncos, LA; Reed, D; Szabó, I, 2013
)
0.67
"Taxol and DCA are potentially nephrotoxic owing their adverse effects on activation of p66shc."( The role of p66shc in taxol- and dichloroacetic acid-dependent renal toxicity.
Arany, I; Clark, JS; Ember, I; Juncos, LA; Reed, D; Szabó, I, 2013
)
0.67
" The effective toxic concentrations of the compounds in these cells were found to be 10-fold higher than those producing similar effects in the mouse liver."( Dichloroacetate and Trichloroacetate Toxicity in AML12 Cells: Role of Oxidative Stress.
Hassoun, E; Mettling, C, 2015
)
0.42

Pharmacokinetics

ExcerptReferenceRelevance
" The time required to elapse between individual doses, in order to prevent second doses having relatively long half-life values, varied in different individuals from 1 week to greater than 3 months."( Disposition and pharmacodynamics of dichloroacetate (DCA) and oxalate following oral DCA doses.
Chu, PI; Curry, SH; Limacher, M; Lorenz, A; Stacpoole, PW, 1991
)
0.28
" At plasma concentrations below 10 micrograms/ml, elimination was monoexponential with a half-life of 32 +/- 11 min (mean +/- SD)."( Metabolic effects and pharmacokinetics of intravenously administered dichloroacetate in humans.
Moore, GW; Oates, JA; Rabin, D; Stacpoole, PW; Wells, PG; Wilkinson, GR, 1980
)
0.26
" One- and two-compartment pharmacokinetic models were fitted to DCA concentrations versus time data using a mixed-effects population approach."( Pharmacokinetics of dichloroacetate in patients undergoing liver transplantation.
Fisher, DM; Shangraw, RE, 1996
)
0.29
" A hybrid, one-compartment pharmacokinetic model fitted best, with zero-order elimination mean of 27."( Reduction of serum lactate by sodium dichloroacetate, and human pharmacokinetic-pharmacodynamic relationships.
Buffini, JD; Fox, AW; Hoehler, FK; Neichin, ML; Nicora, R; O'Rourke, R; Stoltz, RR; Sullivan, BW, 1996
)
0.29
" After intravenous administration, CH rapidly disappeared from blood with a terminal half-life ranging from 5 to 24 min."( Pharmacokinetic analysis of chloral hydrate and its metabolism in B6C3F1 mice.
Abbas, RR; Fisher, JW; Kidney, JK; Seckel, CS, 1996
)
0.29
"The pharmacokinetic properties of the lactate-lowering drug dichloroacetate were investigated in 111 adult patients with lactic acidosis who were randomized to receive dichloroacetate as part of a placebo-controlled clinical trial."( Pharmacokinetics of dichloroacetate in adult patients with lactic acidosis.
Curry, SH; Derendorf, H; Henderson, GN; Stacpoole, PW; Wright, EC, 1997
)
0.3
" Pharmacokinetic analysis indicated that pretreatment significantly decreased total body clearance (267."( Pharmacokinetics and metabolism of dichloroacetate in the F344 rat after prior administration in drinking water.
Bull, RJ; Gonzalez-Leon, A; Schultz, IR; Xu, G, 1997
)
0.3
"A six-compartment physiologically based pharmacokinetic (PBPK) model for the B6C3F1 mouse was developed for trichloroethylene (TCE) and was linked with five metabolite submodels consisting of four compartments each."( A physiologically based pharmacokinetic model for trichloroethylene and its metabolites, chloral hydrate, trichloroacetate, dichloroacetate, trichloroethanol, and trichloroethanol glucuronide in B6C3F1 mice.
Abbas, R; Fisher, JW, 1997
)
0.3
"A physiologically based pharmacokinetic (PBPK) model for inhaled trichloroethylene (TCE) was developed for B6C3F1 mice."( Physiologically based pharmacokinetic modeling of inhaled trichloroethylene and its oxidative metabolites in B6C3F1 mice.
Burton, GA; Fisher, JW; Greenberg, MS, 1999
)
0.3
"The optimal dichloroacetate pharmacokinetic model for both subjects with cirrhosis and control subjects had two compartments, with all parameters weight normalized."( Pharmacokinetics and pharmacodynamics of dichloroacetate in patients with cirrhosis.
Fisher, DM; Shangraw, RE, 1999
)
0.3
" It was the purpose of this study to develop pharmacokinetic and pharmacodynamic models for determination of a dose for a pivotal Phase III clinical trial of DCA in patients with traumatic brain injury (TBI)."( Dichloroacetate: population pharmacokinetics with a pharmacodynamic sequential link model.
Capparelli, EV; Dziewanowska, Z; Fox, AW; Lane, JR; Turkel, CC; Williams, PJ, 2001
)
0.31
"We present the first population pharmacokinetic analysis of quinine in patients with Plasmodium falciparum malaria."( Population pharmacokinetics of intramuscular quinine in children with severe malaria.
Agbenyega, T; Ansong, D; Bedo-Addo, G; Derendorf, H; Henderson, G; Hutson, A; Krishna, S; Nagaraja, NV; Owusu-Ofori, A; Planche, T; Shroads, AL; Stacpoole, PW, 2001
)
0.31
"2 g/L DCA in drinking water for 7 days before initiation of pharmacokinetic studies."( Low-dose pharmacokinetics and oral bioavailability of dichloroacetate in naive and GST-zeta-depleted rats.
Saghir, SA; Schultz, IR, 2002
)
0.31
"3), whereas MCA modified the Cmax (x1."( Evaluation of the influence of chloroacetic acids on the pharmacokinetics of trihalomethanes in the rat.
Krishnan, K; St-Pierre, A; Tardif, R, 2003
)
0.32
" Study end points were calculation of AUC(0-->infinity), apparent volume of distribution (V(ss)), total body clearance (Cl(b)), plasma elimination half-life (t((1/2),beta)), oral absorption rate (K(a)), and oral bioavailability."( Effect of short-term drinking water exposure to dichloroacetate on its pharmacokinetics and oral bioavailability in human volunteers: a stable isotope study.
Schultz, IR; Shangraw, RE, 2006
)
0.33
"Bayesian population analysis of a harmonized physiologically based pharmacokinetic (PBPK) model for trichloroethylene (TCE) and its metabolites was performed."( Bayesian population analysis of a harmonized physiologically based pharmacokinetic model of trichloroethylene and its metabolites.
Chiu, WA; Clewell, HJ; Hack, CE; Jay Zhao, Q, 2006
)
0.33
" A physiologically based pharmacokinetic (PBPK) model was developed to quantitatively describe DCA biotransformation and kinetics in humans administered DCA by intravenous infusion and oral ingestion."( Quantitative evaluation of dichloroacetic acid kinetics in human--a physiologically based pharmacokinetic modeling investigation.
Campbell, JL; Fisher, JW; Keys, DA; Li, T; Schultz, I, 2008
)
0.64
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
"A novel physiologically based pharmacokinetic (PBPK) model structure, which includes submodels for the common metabolites (glyoxylate (GXA) and oxalate (OXA)) that may be involved in the toxicity or carcinogenicity of dibromoacetic acid (DBA), has been developed."( Physiologically based pharmacokinetic modeling of dibromoacetic acid in F344 rats.
Easterling, MR; Matthews, JL; Melnick, RL; Schultz, IR, 2010
)
0.36
"We used data on oxidative and glutathione conjugation metabolism of TCE in 16 inbred and 1 hybrid mouse strains to calibrate and extend existing physiologically based pharmacokinetic (PBPK) models."( Physiologically based pharmacokinetic (PBPK) modeling of interstrain variability in trichloroethylene metabolism in the mouse.
Campbell, JL; Chiu, WA; Clewell, HJ; Guyton, KZ; Rusyn, I; Wright, FA; Zhou, YH, 2014
)
0.4

Compound-Compound Interactions

ExcerptReferenceRelevance
" Given both the good therapeutic effect and low toxicity of these agents, here we investigated whether DCA in combination with ZD55-IL-24 or ONYX-015 could have more efficient antitumor activity in vitro experiments."( Dichloroacetate (DCA) enhances tumor cell death in combination with oncolytic adenovirus armed with MDA-7/IL-24.
Li, X; Niu, N; Qian, J; Wang, Y; Xiao, L; Xie, G, 2010
)
0.36
" In the present study, we aimed to investigate the antitumor effect of DCA combined with 5-Fluorouracil (5-FU) on colorectal cancer (CRC) cells."( Synergistic antitumor effect of dichloroacetate in combination with 5-fluorouracil in colorectal cancer.
He, J; Li, J; Liang, H; Pan, F; Tong, J; Xie, G, 2011
)
0.37
"  To investigate anti-proliferative properties of a novel in silico-modelled 17β-oestradiol derivative (C9), in combination with dichloroacetic acid (DCA), on MCF-7 and MCF-12A cells."( In vitro effects of an in silico-modelled 17β-estradiol derivative in combination with dichloroacetic acid on MCF-7 and MCF-12A cells.
Joubert, AM; Stander, BA; Stander, XX, 2011
)
0.8
"  These results demonstrate that the novel 17β-oestradiol derivative C9, in combination with DCA is a potent anti-proliferation treatment, with properties of selectivity towards tumourigenic cells."( In vitro effects of an in silico-modelled 17β-estradiol derivative in combination with dichloroacetic acid on MCF-7 and MCF-12A cells.
Joubert, AM; Stander, BA; Stander, XX, 2011
)
0.59
" Additive effects were seen when these molecules were combined with 3PO."( Inhibition of Growth of Bladder Cancer Cells by 3-(3-Pyridinyl)-1-(4-pyridinyl)-2-propen-1-one in Combination with Other Compounds Affecting Glucose Metabolism.
Altayyar, M; desBordes, C; Lea, MA, 2015
)
0.42
" We observed that Metformin alone exhibited a dose-dependent anti-leukemic activity in both B leukemic cell lines and primary B-chronic lymphocytic leukemia (B-CLL) patients' cells and its anti-leukemic activity was enhanced when used in combination with DCA."( Metformin combined with sodium dichloroacetate promotes B leukemic cell death by suppressing anti-apoptotic protein Mcl-1.
Bertolasi, V; Casciano, F; Gilli, P; Melloni, E; Rigolin, GM; Rimondi, E; Secchiero, P; Voltan, R; Zauli, G, 2016
)
0.43
" Using unique PGL cell models established in our laboratory, we evaluated the effect of dichloroacetate (DCA) as single agent or in a novel combination with other metabolic drugs, including GW6471 and metformin."( Effects of dichloroacetate as single agent or in combination with GW6471 and metformin in paraganglioma cells.
Amoroso, R; Arduini, A; Cama, A; Cataldi, A; De Lellis, L; di Giacomo, V; Florio, R; Gallorini, M; Mariani-Costantini, R; Natale, A; Perconti, S; Sanna, M; Verginelli, F; Veschi, S, 2018
)
0.48

Bioavailability

ExcerptReferenceRelevance
" We attempted to alter DCA pharmacokinetics and bioavailability by synthesizing various derivatives comprising DCA esters with polyols and DCA ionic complexes."( Dichloroacetate derivatives. Metabolic effects and pharmacodynamics in normal rats.
Bodor, N; Gonzalez, MG; Oshiro, Y; Stacpoole, PW; Vlasak, J, 1987
)
0.27
" Oral bioavailability of DCA was 0-13% in naive and 14-75% in GST-zeta- depleted rats."( Low-dose pharmacokinetics and oral bioavailability of dichloroacetate in naive and GST-zeta-depleted rats.
Saghir, SA; Schultz, IR, 2002
)
0.31
" We measured DCAA bioavailability in 16 human volunteers (eight men, eight women) after simultaneous administration of oral and iv DCAA doses."( Effect of short-term drinking water exposure to dichloroacetate on its pharmacokinetics and oral bioavailability in human volunteers: a stable isotope study.
Schultz, IR; Shangraw, RE, 2006
)
0.33
"Dichloroacetate (DCA) is a highly bioavailable small molecule that inhibits pyruvate dehydrogenase kinase, promoting glucose oxidation and reversing the glycolytic phenotype in preclinical cancer studies."( Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer.
Bahng, A; Black, A; Britten, CD; Christofk, HR; Crabtree, MJ; Dubinett, SM; Garon, EB; Hong, CS; Hosmer, W; Kabbinavar, F; Kamranpour, N; Michelakis, ED; Patel, C; Pitts, S; Slamon, DJ; von Euw, E, 2014
)
0.4
" However, its molecular form shows poor uptake and bioavailability and limited ability to reach its target mitochondria."( Mito-DCA: a mitochondria targeted molecular scaffold for efficacious delivery of metabolic modulator dichloroacetate.
Dhar, S; Harn, DA; Marrache, S; Pathak, RK, 2014
)
0.4
" However, DCA molecule exhibits poor bioavailability and cellular uptake with limited ability to reach its target mitochondria."( Design, Synthesis, and Biological Characterization of Novel Mitochondria Targeted Dichloroacetate-Loaded Compounds with Antileukemic Activity.
Bianco, S; Celeghini, C; Fantinati, A; Guerrini, R; Melloni, E; Salvadori, S; Secchiero, P; Tisato, V; Trapella, C; Voltan, R; Zauli, G, 2016
)
0.43
" In order to overcome the problems of poor bioavailability and cellular uptake, which limit DCA efficacy, we have designed and synthetized cocrystals consisting of Metformin and DCA (Met-DCA) at different stoichiometric ratios."( Metformin combined with sodium dichloroacetate promotes B leukemic cell death by suppressing anti-apoptotic protein Mcl-1.
Bertolasi, V; Casciano, F; Gilli, P; Melloni, E; Rigolin, GM; Rimondi, E; Secchiero, P; Voltan, R; Zauli, G, 2016
)
0.43
" Exposure to HAAs is influenced by consumption patterns and diet of individuals thus their bioavailability is an important parameter to the overall toxicity."( In vitro bioacessibility and transport across Caco-2 monolayers of haloacetic acids in drinking water.
Faria, MA; Ferreira, IMPLVO; Mansilha, C; Melo, A; Pinto, E, 2016
)
0.43
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" New drug delivery systems and multiaction compounds containing DCA and other drugs seem to ameliorate bioavailability and appear more efficient thanks to a synergistic action of multiple agents."( Dichloroacetate (DCA) and Cancer: An Overview towards Clinical Applications.
Piccoli, C; Tataranni, T, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" We examined the in vivo adduction of the blood proteins hemoglobin (Hb) and albumin in rats and mice dosed orally with [14C]trichloroethylene ([14C]TRI) to explore the development of a protein adduct biomarker of TRI exposure."( Adduction of hemoglobin and albumin in vivo by metabolites of trichloroethylene, trichloroacetate, and dichloroacetate in rats and mice.
Bull, RJ; Eyre, RJ; Stevens, DK, 1992
)
0.28
" In two separate studies, animals were dosed by oral intubation on gestation days 6-15 (plug = 0) with 0, 900, 1,400, 1,900 or 2,400 mg/kg/day and 0, 14, 140, or 400 mg/kg/day."( Developmental toxicity of dichloroacetate in the rat.
Randall, JL; Read, EJ; Smith, MK; Stober, JA, 1992
)
0.28
" In a series of three studies, groups of 7-10 Long-Evans rats were dosed with 1,900 mg/kg of DCA on days 6-8, 9-11, or 12-15; with 2,400 mg/kg on days 10, 11, 12, or 13; and with 3,500 mg/kg on days 9, 10, 11, 12, or 13, in an attempt to determine the most sensitive period and further characterize the heart defect."( Cardiopathic effects of dichloroacetate in the fetal Long-Evans rat.
Christ, SA; Epstein, DL; Nolen, GA; Randall, JL; Read, EJ; Smith, MK; Stober, JA, 1992
)
0.28
" Males pretreated with MCA had 45-fold greater plasma alanine aminotransferase (ALT) compared to the saline pretreated group similarly dosed with CHCl3."( Sex differences in monochloroacetate pretreatment effects on chloroform toxicity in rats.
Berndt, WO; Davis, ME, 1992
)
0.28
"Male and female juvenile beagle dogs were dosed daily for 90 days with dichloroacetate (DCA)."( 90-Day toxicity study of dichloroacetate in dogs.
Cicmanec, JL; Condie, LW; Olson, GR; Wang, SR, 1991
)
0.28
" The dose-response nature of ischemic injury and neurological outcome in this rat model of paraplegia therefore appears to play an important role in determining the effect observed with a specific intervention."( Neurological protection by dichloroacetate depending on the severity of injury in the paraplegic rat.
D'Alecy, LG; LeMay, DR; Zelenock, GB, 1990
)
0.28
" The previously unstudied dose-response also was evaluated in our study."( Effects of various doses of sodium dichloroacetate on hyperlactatemia in fed ischemic rats.
Dimlich, RV; Kaplan, J; Timerding, BL; Van Ligten, PF, 1989
)
0.28
" Animals were dosed by oral intubation on Gestation Days 6-18 (plug = 0) with 0, 5, 15, 25, or 45 mg/kg/day."( Developmental toxicity of dichloroacetonitrile: a by-product of drinking water disinfection.
Randall, JL; Read, EJ; Smith, MK; Stober, JA, 1989
)
0.28
" Dosing F344 rats with 200 mg/kg TCA in water or corn oil for 10 days increased peroxisome proliferation 179 and 278%, respectively, above the vehicle controls."( Species and strain sensitivity to the induction of peroxisome proliferation by chloroacetic acids.
Daniel, FB; DeAngelo, AB; McMillan, L; Savage, RE; Wernsing, P, 1989
)
0.28
" Because higher doses of DCA may be more effective, the main objective of our study was to examine the dose-response of brain tissue lactate to DCA."( Effects of sodium dichloroacetate dose. Brain metabolites associated with cerebral ischemia.
Cammenga, R; Dimlich, RV; Kaplan, J; Timerding, BL; Van Ligten, PF, 1989
)
0.28
" The methoxydifluoroacetate is largely excreted without further metabolism, although a small percentage of this metabolite is broken down to yield fluoride and oxalate, as determined by urine analysis of rats dosed with synthetic methoxydifluoroacetate."( In vivo nuclear magnetic resonance studies of hepatic methoxyflurane metabolism. II. A reevaluation of hepatic metabolic pathways.
London, RE; Perlman, ME; Selinsky, BS, 1988
)
0.27
" Chronic daily dosing caused lowering of these metabolites and a delay in the return of lactate to basal levels for 48 hr after the final dose."( Prolonged hypolactatemia and increased total pyruvate dehydrogenase activity by dichloroacetate.
Evans, OB; Stacpoole, PW, 1982
)
0.26
" Animals were dosed every 4th day for 6 weeks and euthanized 24 hr following the last dose."( Trichloroethene-induced autoimmune response in female MRL +/+ mice.
Ansari, GA; Kanz, MF; Kaphalia, BS; Khan, MF; Prabhakar, BS, 1995
)
0.29
"0 g/l, and CAA to CTA was present in 29% and 34% of the two dosage groups respectively."( Ras oncogene activation during hepatocarcinogenesis in B6C3F1 male mice by dichloroacetic and trichloroacetic acids.
DeAngelo, AB; Ferreira-Gonzalez, A; Garrett, CT; Nasim, S, 1995
)
0.29
"Pretreatment of male B6C3F1 mice with clofibric acid (CFA) or trichloroacetic acid (TCA) in the drinking water results in a marked decrease in the lipoperoxidative response as measured by the production of thiobarbituric acid reactive substances (TBARS) in mouse liver homogenates following acute dosing with TCA or dichloroacetic acid (DCA)."( Modification of lipoperoxidative effects of dichloroacetate and trichloroacetate is associated with peroxisome proliferation.
Austin, EW; Bull, RJ; Larson, JL; Okita, JR; Okita, RT, 1995
)
0.46
" DCA, proposes a simple pharmacokinetic model for its elimination, characterizes the dose-response relationship in terms of time course of effect, shows the dissociation between elimination of DCA and offset of response and will guide further studies of DCA in patients with head injury or stroke."( Reduction of serum lactate by sodium dichloroacetate, and human pharmacokinetic-pharmacodynamic relationships.
Buffini, JD; Fox, AW; Hoehler, FK; Neichin, ML; Nicora, R; O'Rourke, R; Stoltz, RR; Sullivan, BW, 1996
)
0.29
" Mice were dosed with 67."( Pharmacokinetic analysis of chloral hydrate and its metabolism in B6C3F1 mice.
Abbas, RR; Fisher, JW; Kidney, JK; Seckel, CS, 1996
)
0.29
" Delayed spermiation and formation of atypical residual bodies also were observed on days 2, 5, 9, and 14 in rats dosed daily with 1440, 480, 160, and 54 mg/kg."( Spermatotoxicity of dichloroacetic acid.
Klinefelter, GR; Linder, RE; Roberts, NL; Strader, LF; Suarez, JD,
)
0.45
" Differences in dose-response curves, progression to cancer, and postexposure regression of lesions suggest that TCA and DCA work through different mechanisms."( Dissimilar characteristics of N-methyl-N-nitrosourea-initiated foci and tumors promoted by dichloroacetic acid or trichloroacetic acid in the liver of female B6C3F1 mice.
Latendresse, JR; Pereira, MA,
)
0.35
" For oral bolus dosing of TCE with 300, 600, and 2000 mg/kg, model predictions of TCE and several metabolites were in general agreement with observations."( A physiologically based pharmacokinetic model for trichloroethylene and its metabolites, chloral hydrate, trichloroacetate, dichloroacetate, trichloroethanol, and trichloroethanol glucuronide in B6C3F1 mice.
Abbas, R; Fisher, JW, 1997
)
0.3
" The IPRL system was dosed with either 5 or 50 micromol of either TCA or DCA (25 or 250 microM initial concentration, respectively)."( Kinetics of trichloroacetic acid and dichloroacetic acid in the isolated perfused rat liver.
Frazier, JM; Toxopeus, C, 1998
)
0.57
" The effect of fasting for 14 hr before dosing was studied."( Pharmacokinetics and metabolism of [14C]dichloroacetate in male Sprague-Dawley rats. Identification of glycine conjugates, including hippurate, as urinary metabolites of dichloroacetate.
Cornett, R; Davydova, N; Henderson, GN; James, MO; Jayanti, VM; Katovich, MJ; Pollock, B; Stacpoole, PW; Yan, Z, 1998
)
0.3
" Male B6C3F1 mice were dosed with TRI, CH, trichloroethanol (TCE), or TCA and metabolic profiles of each were determined."( The extent of dichloroacetate formation from trichloroethylene, chloral hydrate, trichloroacetate, and trichloroethanol in B6C3F1 mice.
Bull, RJ; Gonzalez-Leon, A; Merdink, JL; Schultz, IR, 1998
)
0.3
" These new guidelines provide the latitude to consider diverse scientific data and allow considerable flexibility in dose-response assessments, depending on the chemical's mode of action."( Lessons learned in applying the U.S. EPA proposed cancer guidelines to specific compounds.
Andersen, ME; Boorman, GA; Brusick, DJ; Cohen, SM; Dragan, YP; Frederick, CB; Goodman, JI; Hard, GC; Meek, ME; O'Flaherty, EJ; Robinson, DE, 2000
)
0.31
" Simulations were employed to evaluate various dosing strategies for consideration in a pivotal Phase III clinical trial of DCA."( Dichloroacetate: population pharmacokinetics with a pharmacodynamic sequential link model.
Capparelli, EV; Dziewanowska, Z; Fox, AW; Lane, JR; Turkel, CC; Williams, PJ, 2001
)
0.31
" Soybean oil is commonly used as a dosing vehicle for RA teratology studies and was also used in this study as a dosing vehicle for TCE."( Trichloroethylene, trichloroacetic acid, and dichloroacetic acid: do they affect fetal rat heart development?
Channel, SR; Eggers, JS; Fisher, JW; Goodyear, CD; Graeter, LJ; Johnson, PD; Latendresse, JR; MacMahon, KL; Sudberry, GL; Warren, DA,
)
0.39
" The dosage of DCA should be adjusted for each patient."( [Adverse effects of dichloroacetate in a girl with mitochondrial disorder].
Fukumizu, M; Hanaoka, S; Hirayama, Y; Izumi, M; Kaga, M; Murayama, K; Sasaki, M; Sugai, K, 2003
)
0.32
"2 h for a subsequent intravenous dose 4-6 h later, and 11 h after continued oral dosing of 12."( Chronic treatment of mitochondrial disease patients with dichloroacetate.
Barshop, BA; Haas, RH; Levine, F; Loupis-Geller, A; McGowan, KA; Naviaux, RK; Nyhan, WL,
)
0.13
" Levels of DCA found in rats dosed with 2 g/kg TCE were 17."( Analysis of dichloroacetic acid in rat blood and tissues by hydrophilic interaction liquid chromatography with tandem mass spectrometry.
Bartlett, MG; Bruckner, JV; Delinsky, AD; Delinsky, DC; Fisher, JW; Muralidhara, S, 2005
)
0.71
" To increase sensitivity, analytes were extracted from liver, urine, plasma and cultured nerve cells before and after dosing with DCA, derivatized to their pentafluorobenzyl esters, and analyzed via GC-MS/MS."( A GC-MS/MS method for the quantitative analysis of low levels of the tyrosine metabolites maleylacetone, succinylacetone, and the tyrosine metabolism inhibitor dichloroacetate in biological fluids and tissues.
Henderson, GN; Jia, M; Liu, H; Stacpoole, PW; Zolodz, MD, 2006
)
0.33
" This analysis provides an important step toward estimating uncertainty of dose-response relationships in noncancer and cancer risk assessment, improving the extrapolation of toxic TCE doses from experimental animals to humans."( Bayesian population analysis of a harmonized physiologically based pharmacokinetic model of trichloroethylene and its metabolites.
Chiu, WA; Clewell, HJ; Hack, CE; Jay Zhao, Q, 2006
)
0.33
" Low concentrations of monochloroacetate (MCA), which is known to be neurotoxic, increase as a function of age in the urine of dosed rats."( Age-dependent kinetics and metabolism of dichloroacetate: possible relevance to toxicity.
Dixit, V; Guo, X; James, MO; Liu, HP; Shroads, AL; Stacpoole, PW, 2008
)
0.35
" Survival of dosed males and females was similar to that of the vehicle control groups for both studies."( NTP report on the toxicology studies of dichloroacetic acid (CAS No. 79-43-6) in genetically modified (FVB Tg.AC hemizygous) mice (dermal and drinking water studies) and carcinogenicity studies of dichloroacetic acid in genetically modified [B6.129-Trp53(
, 2007
)
0.61
" Based on similarities of TCE and TCA to typical PP, including dose-response characteristics showing PPARalpha-dependent responses coincident with liver tumor induction and abolishment of TCE and TCA effects in PPARalpha-null mice, the WOE supports the hypothesis that PPARalpha plays a dominant role in TCE- and TCA-induced hepatocarcinogenesis."( Evaluation of the role of peroxisome proliferator-activated receptor alpha (PPARalpha) in mouse liver tumor induction by trichloroethylene and metabolites.
Corton, JC, 2008
)
0.35
" Dosing was based on haplotype variation in glutathione transferase zeta 1/maleylacetoacetate isomerase (GSTZ1/MAAI), which participates in DCA and tyrosine catabolism."( Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors.
Coats, BS; Dunbar, EM; Forder, JR; Langaee, T; Lew, A; Shroads, AL; Shuster, JJ; Stacpoole, PW; Wagner, DA, 2014
)
0.4
" The importance of genetic-based dosing is confirmed and should be incorporated into future trials of chronic DCA administration."( Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors.
Coats, BS; Dunbar, EM; Forder, JR; Langaee, T; Lew, A; Shroads, AL; Shuster, JJ; Stacpoole, PW; Wagner, DA, 2014
)
0.4
" Although DCA itself may be of limited therapeutic value in a clinical setting due to its low threshold of dosage and high toxicity, this proof of concept study does suggest that the addition of a physiological-based mitochondrial stimulator to embryo culture media for aged women may potentially improve IVF outcomes."( Stimulation of mitochondrial embryo metabolism by dichloroacetic acid in an aged mouse model improves embryo development and viability.
Lane, M; McPherson, NO; Zander-Fox, D, 2014
)
0.66
" Because the in vivo half-life of DCA is determined by the fraction of active GSTZ1 in the liver, identifying factors that regulate GSTZ1 activity is important in determining appropriate DCA dosing in humans."( Chloride and other anions inhibit dichloroacetate-induced inactivation of human liver GSTZ1 in a haplotype-dependent manner.
Gu, Y; James, MO; Langaee, T; Li, W; Stacpoole, PW; Zhong, G, 2014
)
0.4
"4 μg/mL), metabolized from CH, was measured on the fifth day of the 1 g/day CH dosage but was undetectable in plasma at environmentally relevant doses."( Chloral hydrate, through biotransformation to dichloroacetate, inhibits maleylacetoacetate isomerase and tyrosine catabolism in humans.
Coats, BS; Langaee, T; Shroads, AL; Shuster, JJ; Stacpoole, PW, 2015
)
0.42
" Oral dosing with TCE was conducted in subacute (600 mg/kg/d; 5 d; 7 inbred mouse strains) and subchronic (100 or 400 mg/kg/d; 1, 2, or 4 wk; 2 inbred mouse strains) designs."( Comparative analysis of the relationship between trichloroethylene metabolism and tissue-specific toxicity among inbred mouse strains: liver effects.
Ball, LM; Bodnar, WM; Bradford, BU; Collins, LB; Gold, A; Kosyk, O; Rusyn, I; Shymonyak, S; Uehara, T; Yoo, HS, 2015
)
0.42
" Oral dosing with TCE was conducted in subacute (600 mg/kg/d; 5 d; 7 inbred mouse strains) and subchronic (100 or 400 mg/kg/d; 1, 2, or 4 wk; 2 inbred mouse strains) designs."( Comparative analysis of the relationship between trichloroethylene metabolism and tissue-specific toxicity among inbred mouse strains: kidney effects.
Ball, LM; Bodnar, WM; Bradford, BU; Collins, LB; Gold, A; Kosyk, O; Rusyn, I; Shymonyak, S; Uehara, T; Yoo, HS, 2015
)
0.42
" These results further define safe, genetics-based dosing regimens for chronic DCA administration."( The influence of human GSTZ1 gene haplotype variations on GSTZ1 expression.
Hamadeh, I; James, MO; Langaee, TY; Li, W; McDonough, CW; Solayman, MH; Stacpoole, PW; Zhong, G, 2015
)
0.42
" Dosage of DCA had a moderate effect of its anticancer action."( Effectiveness of sodium dichloroacetate against glioma C6 depends on administration schedule and dosage.
Fedorchuk, AG; Gorbik, GV; Kolesnik, DL; Prokhorova, IV; Pyaskovskaya, ON; Solyanik, GI, 2016
)
0.43
"These preliminary data establish the validity and practicality of our rapid genotyping/haplotyping procedure for genetic-based DCA dosing to mitigate or prevent adverse effects in patients treated chronically with this drug."( Personalized Dosing of Dichloroacetate Using GSTZ1 Clinical Genotyping Assay.
Becker, C; Horne, LP; Langaee, T; Lawson, LA; Shahin, M; Stacpoole, PW; Starostik, P; Wagner, R, 2018
)
0.48
" In this work preformulation studies on the active molecule were performed to identify those physico-chemical properties of the drug relevant to the design of the dosage forms and their process of manufacture."( Pharmaceutical preformulation studies and paediatric oral formulations of sodium dichloroacetate.
Curci, A; Cutrignelli, A; Denora, N; Franco, M; Laquintana, V; Lopalco, A; Lopedota, A, 2019
)
0.51
" Clinical research into the anti-cancer activity of DCA revealed high dosage requirements and reports of toxicity."( Two dichloric compounds inhibit in vivo U87 xenograft tumor growth.
Chitjian, C; Fanelli, A; Kashkin, A; Ovcharenko, D; Ovcharenko, V, 2019
)
0.51
" Repeated dosing of DCA results in reduced drug clearance due to inactivation of glutathione transferase ζ1 (GSTZ1), its metabolizing enzyme."( Mitochondrial Glutathione Transferase Zeta 1 Is Inactivated More Rapidly by Dichloroacetate than the Cytosolic Enzyme in Adult and Juvenile Rat Liver.
Horne, LP; Hu, Z; Jahn, SC; James, MO; Rowland-Faux, L; Smeltz, MG; Stacpoole, PW; Zhong, G, 2019
)
0.51
" Here, we examined the expression and activity of GSTZ1 in cytosol and mitochondria of liver, kidney, heart, and brain 24 hours after completion of 8-day oral dosing of 100 mg/kg per day sodium DCA to juvenile and adult Sprague Dawley rats."( Effects of Multiple Doses of Dichloroacetate on GSTZ1 Expression and Activity in Liver and Extrahepatic Tissues of Young and Adult Rats.
Horne, LP; James, MO; Rowland-Faux, L; Smeltz, MG; Squirewell, EJ; Stacpoole, PW, 2020
)
0.56
" Haplotype variations in GSTZ1 influence the rate of DCA metabolism, enabling a genotyping strategy to allow potentially safe, precision-based drug dosing in clinical trials."( Clinical physiology and pharmacology of GSTZ1/MAAI.
Stacpoole, PW, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
astringentA compound that causes the contraction of body tissues, typically used to reduce bleeding from minor abrasions.
marine metaboliteAny metabolite produced during a metabolic reaction in marine macro- and microorganisms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
monocarboxylic acidAn oxoacid containing a single carboxy group.
organochlorine compoundAn organochlorine compound is a compound containing at least one carbon-chlorine bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (15)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AR proteinHomo sapiens (human)Potency18.75540.000221.22318,912.5098AID1259243; AID743035
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency3.35740.000214.376460.0339AID588532; AID720691
retinoid X nuclear receptor alphaHomo sapiens (human)Potency3.99310.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency54.72290.001530.607315,848.9004AID1224849; AID1259403
estrogen nuclear receptor alphaHomo sapiens (human)Potency56.31840.000229.305416,493.5996AID743075; AID743077
activating transcription factor 6Homo sapiens (human)Potency56.57170.143427.612159.8106AID1159516
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency0.15850.010039.53711,122.0200AID588545
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency61.13060.000323.4451159.6830AID743066
lethal factor (plasmid)Bacillus anthracis str. A2012Potency5.01190.020010.786931.6228AID912
lamin isoform A-delta10Homo sapiens (human)Potency0.07080.891312.067628.1838AID1487
Cellular tumor antigen p53Homo sapiens (human)Potency6.11310.002319.595674.0614AID651631
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrialHomo sapiens (human)IC50 (µMol)1,677.60000.00051.89099.5000AID1368158; AID1442053; AID162967; AID1802790
[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrialHomo sapiens (human)IC50 (µMol)2,353.40000.06503.12999.5000AID1368160; AID1442055; AID162967; AID1802790
[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrialHomo sapiens (human)IC50 (µMol)1,955.75000.02603.56669.5000AID1442066; AID162967; AID1802790
[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrialHomo sapiens (human)IC50 (µMol)747.50000.02103.58609.5000AID1442071; AID162967; AID1802790
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (149)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
glucose metabolic process[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrialHomo sapiens (human)
cell population proliferation[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrialHomo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stress[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrialHomo sapiens (human)
regulation of acetyl-CoA biosynthetic process from pyruvate[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrialHomo sapiens (human)
regulation of glucose metabolic process[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrialHomo sapiens (human)
hypoxia-inducible factor-1alpha signaling pathway[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrialHomo sapiens (human)
protein phosphorylation[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrialHomo sapiens (human)
glucose metabolic process[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrialHomo sapiens (human)
regulation of gluconeogenesis[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrialHomo sapiens (human)
regulation of pH[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrialHomo sapiens (human)
insulin receptor signaling pathway[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrialHomo sapiens (human)
regulation of acetyl-CoA biosynthetic process from pyruvate[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrialHomo sapiens (human)
regulation of cellular ketone metabolic process[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrialHomo sapiens (human)
regulation of glucose metabolic process[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrialHomo sapiens (human)
cellular response to nutrient[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrialHomo sapiens (human)
cellular response to reactive oxygen species[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrialHomo sapiens (human)
glucose homeostasis[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrialHomo sapiens (human)
regulation of calcium-mediated signaling[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrialHomo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediator[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrialHomo sapiens (human)
protein phosphorylation[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrialHomo sapiens (human)
regulation of acetyl-CoA biosynthetic process from pyruvate[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrialHomo sapiens (human)
regulation of glucose metabolic process[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrialHomo sapiens (human)
peptidyl-serine phosphorylation[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrialHomo sapiens (human)
peroxisome proliferator activated receptor signaling pathway[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrialHomo sapiens (human)
cellular response to fatty acid[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrialHomo sapiens (human)
hypoxia-inducible factor-1alpha signaling pathway[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrialHomo sapiens (human)
regulation of reactive oxygen species metabolic process[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrialHomo sapiens (human)
protein phosphorylation[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrialHomo sapiens (human)
regulation of pH[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrialHomo sapiens (human)
insulin receptor signaling pathway[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrialHomo sapiens (human)
cellular response to starvation[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrialHomo sapiens (human)
regulation of acetyl-CoA biosynthetic process from pyruvate[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrialHomo sapiens (human)
regulation of cellular ketone metabolic process[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrialHomo sapiens (human)
regulation of glucose metabolic process[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrialHomo sapiens (human)
regulation of fatty acid biosynthetic process[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrialHomo sapiens (human)
glucose homeostasis[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrialHomo sapiens (human)
response to starvation[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrialHomo sapiens (human)
regulation of bone resorption[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrialHomo sapiens (human)
regulation of fatty acid oxidation[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrialHomo sapiens (human)
cellular response to fatty acid[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrialHomo sapiens (human)
reactive oxygen species metabolic process[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrialHomo sapiens (human)
negative regulation of anoikis[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrialHomo sapiens (human)
protein phosphorylation[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (39)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
protein kinase activity[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrialHomo sapiens (human)
pyruvate dehydrogenase (acetyl-transferring) kinase activity[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrialHomo sapiens (human)
protein binding[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrialHomo sapiens (human)
ATP binding[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrialHomo sapiens (human)
protein kinase activity[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrialHomo sapiens (human)
pyruvate dehydrogenase (acetyl-transferring) kinase activity[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrialHomo sapiens (human)
protein binding[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrialHomo sapiens (human)
ATP binding[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrialHomo sapiens (human)
protein homodimerization activity[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrialHomo sapiens (human)
protein kinase activity[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrialHomo sapiens (human)
protein serine/threonine kinase activity[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrialHomo sapiens (human)
pyruvate dehydrogenase (acetyl-transferring) kinase activity[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrialHomo sapiens (human)
protein binding[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrialHomo sapiens (human)
ATP binding[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrialHomo sapiens (human)
protein kinase activity[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrialHomo sapiens (human)
pyruvate dehydrogenase (acetyl-transferring) kinase activity[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrialHomo sapiens (human)
protein binding[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrialHomo sapiens (human)
ATP binding[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (20)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrix[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrialHomo sapiens (human)
mitochondrion[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrialHomo sapiens (human)
nucleoplasm[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrialHomo sapiens (human)
mitochondrion[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrialHomo sapiens (human)
mitochondrial matrix[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrialHomo sapiens (human)
cytosol[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrialHomo sapiens (human)
pyruvate dehydrogenase complex[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrialHomo sapiens (human)
mitochondrion[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrialHomo sapiens (human)
nucleolus[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrialHomo sapiens (human)
mitochondrion[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrialHomo sapiens (human)
mitochondrial matrix[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrialHomo sapiens (human)
mitochondrion[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrialHomo sapiens (human)
mitochondrial matrix[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrialHomo sapiens (human)
mitochondrion[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (122)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1442066Inhibition of PDK3 (unknown origin) using full length His6-tagged PDHA1 as substrate after 30 mins by ELISA
AID1613803Antiproliferative activity against human BEAS2B cells assessed as reduction in cell viability after 72 hrs by MTT assay2019European journal of medicinal chemistry, Feb-15, Volume: 164High-throughput screening of novel pyruvate dehydrogenase kinases inhibitors and biological evaluation of their in vitro and in vivo antiproliferative activity.
AID1442077Antiproliferative activity against human Kelly cells after 72 hrs by CCK8 assay
AID1402706Antiproliferative activity against human HeLa cells after 24 hrs by MTT assay2018European journal of medicinal chemistry, Jan-20, Volume: 144Design and characterization of α-lipoic acyl shikonin ester twin drugs as tubulin and PDK1 dual inhibitors.
AID237685Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
AID1604098Induction of mitochondrial depolarization in human H1299 cells assessed as increase in oxygen consumption rate at 10 uM measured for 1 hr by seahorse XFe96 analyser based assay
AID1613829Inhibition of PDK1 in human NCI-H1975 cells assessed as switch of pyruvate metabolism from lactate production to oxidative phosphorylation by measuring increase in oxygen consumption rates at 10 mM measured after 4 hrs by XFe24 extracellular flux analyzer2019European journal of medicinal chemistry, Feb-15, Volume: 164High-throughput screening of novel pyruvate dehydrogenase kinases inhibitors and biological evaluation of their in vitro and in vivo antiproliferative activity.
AID1402708Antiproliferative activity against human LO2 cells after 24 hrs by MTT assay2018European journal of medicinal chemistry, Jan-20, Volume: 144Design and characterization of α-lipoic acyl shikonin ester twin drugs as tubulin and PDK1 dual inhibitors.
AID1613798Antiproliferative activity against human NCI-H1975 cells assessed as reduction in cell viability after 72 hrs by MTT assay2019European journal of medicinal chemistry, Feb-15, Volume: 164High-throughput screening of novel pyruvate dehydrogenase kinases inhibitors and biological evaluation of their in vitro and in vivo antiproliferative activity.
AID1271724Cell cycle arrest in human JVM2 cells assessed as accumulation at S phase at 30 mM after 48 hrs by BrdU/PI-staining based FACS analysis (Rvb = 40%)2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Design, Synthesis, and Biological Characterization of Novel Mitochondria Targeted Dichloroacetate-Loaded Compounds with Antileukemic Activity.
AID1271715Induction of apoptosis in human primary B-CLL cells assessed as late apoptotic cells at 30 mM after 48 hrs by annexin V-FITC/PI-staining based FACS analysis (Rvb = 8.5%)2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Design, Synthesis, and Biological Characterization of Novel Mitochondria Targeted Dichloroacetate-Loaded Compounds with Antileukemic Activity.
AID1271692Cytotoxicity against human JVM2 cells after 48 hrs by MTT assay2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Design, Synthesis, and Biological Characterization of Novel Mitochondria Targeted Dichloroacetate-Loaded Compounds with Antileukemic Activity.
AID1402709Antiproliferative activity against human 293T cells after 24 hrs by MTT assay2018European journal of medicinal chemistry, Jan-20, Volume: 144Design and characterization of α-lipoic acyl shikonin ester twin drugs as tubulin and PDK1 dual inhibitors.
AID1604108Induction of apoptosis in human DU145 cells assessed as increase in PARP cleavage by Western blot analysis
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1536193Inhibition of PDK4 in HEK293T cells assessed as reduction in PDHE1alpha phosphorylation at Ser-232 residue by measuring phosphorylated PDHE1alpha level at 5 mM after 24 hrs by Western blot analysis (Rvb = 1 No_unit)2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Discovery of Novel Pyruvate Dehydrogenase Kinase 4 Inhibitors for Potential Oral Treatment of Metabolic Diseases.
AID1368172Anti-proliferative activity against human MG63 cells after 72 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 12-15, Volume: 27, Issue:24
Identification of pyruvate dehydrogenase kinase 1 inhibitors with anti-osteosarcoma activity.
AID1604111Synergistic antiproliferative activity against human H1299 cells at 20 uM incubated for 72 hrs in presence of satra-platin by CellTiter-Glo assay relative to control
AID1368160Inhibition of recombinant human GST-tagged PDK2 expressed in baculovirus infected Sf9 cells using PDHA1 as substrate measured after 1 hr by ELISA2017Bioorganic & medicinal chemistry letters, 12-15, Volume: 27, Issue:24
Identification of pyruvate dehydrogenase kinase 1 inhibitors with anti-osteosarcoma activity.
AID1271694Cytotoxicity against human HL60 cells after 48 hrs by MTT assay2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Design, Synthesis, and Biological Characterization of Novel Mitochondria Targeted Dichloroacetate-Loaded Compounds with Antileukemic Activity.
AID1613834Inhibition of porcine PDK assessed as activation of pyruvate dehydrogenase complex at 10 mM measured after 3 mins relative to control2019European journal of medicinal chemistry, Feb-15, Volume: 164High-throughput screening of novel pyruvate dehydrogenase kinases inhibitors and biological evaluation of their in vitro and in vivo antiproliferative activity.
AID1402704Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay2018European journal of medicinal chemistry, Jan-20, Volume: 144Design and characterization of α-lipoic acyl shikonin ester twin drugs as tubulin and PDK1 dual inhibitors.
AID131109In vivo activity in a diabetic mouse at a dose of 1000 umol/kg/day on day1 after 4 hr1999Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15
Triterpene and diterpene inhibitors of pyruvate dehydrogenase kinase (PDK).
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1817653Inhibition of glycolysis in human A549 cells assessed as reduction in lactate production incubated for 8 hrs by colorimetric-oxidase mediator analysis2021Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14
Carbohydrate-Based NK1R Antagonists with Broad-Spectrum Anticancer Activity.
AID1613802Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay2019European journal of medicinal chemistry, Feb-15, Volume: 164High-throughput screening of novel pyruvate dehydrogenase kinases inhibitors and biological evaluation of their in vitro and in vivo antiproliferative activity.
AID1604103Induction of apoptosis in human H1299 cells assessed as increase in apoptotic cells at 30 uM incubated for 48 hrs by FITC Annexin-V and PI staining based flow cytometric analysis relative to control
AID1368158Inhibition of recombinant human GST-tagged PDK1 expressed in baculovirus infected Sf9 cells using PDHA1 as substrate measured after 1 hr by ELISA2017Bioorganic & medicinal chemistry letters, 12-15, Volume: 27, Issue:24
Identification of pyruvate dehydrogenase kinase 1 inhibitors with anti-osteosarcoma activity.
AID1402707Antiproliferative activity against human A549 cells after 24 hrs by MTT assay2018European journal of medicinal chemistry, Jan-20, Volume: 144Design and characterization of α-lipoic acyl shikonin ester twin drugs as tubulin and PDK1 dual inhibitors.
AID1613828Inhibition of PDK1 in human NCI-H1975 cells assessed as switch of pyruvate metabolism from lactate production to oxidative phosphorylation by measuring decrease in extracellular acidification rate at 10 mM measured after 4 hrs by XFe24 extracellular flux 2019European journal of medicinal chemistry, Feb-15, Volume: 164High-throughput screening of novel pyruvate dehydrogenase kinases inhibitors and biological evaluation of their in vitro and in vivo antiproliferative activity.
AID1613797Antiproliferative activity against human NCI-H1650 cells assessed as reduction in cell viability after 72 hrs by MTT assay2019European journal of medicinal chemistry, Feb-15, Volume: 164High-throughput screening of novel pyruvate dehydrogenase kinases inhibitors and biological evaluation of their in vitro and in vivo antiproliferative activity.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1402794Inhibition of PDK1 in human HeLa cells assessed as decrease in PDH-E1 alpha p-ser300 expression at 10 mM by Western blot analysis2018European journal of medicinal chemistry, Jan-20, Volume: 144Design and characterization of α-lipoic acyl shikonin ester twin drugs as tubulin and PDK1 dual inhibitors.
AID1442079Antiproliferative activity against human LO2 cells after 72 hrs by CCK8 assay
AID1368170Inhibition of PDK1 in human MG63 cells assessed as reduction in pyruvate dehydrogenase complex phosphorylation at ser293 residue at 10 mM after 24 hrs by Western blot analysis2017Bioorganic & medicinal chemistry letters, 12-15, Volume: 27, Issue:24
Identification of pyruvate dehydrogenase kinase 1 inhibitors with anti-osteosarcoma activity.
AID1271706Cytotoxicity against human MEC1 cells after 48 hrs by MTT assay2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Design, Synthesis, and Biological Characterization of Novel Mitochondria Targeted Dichloroacetate-Loaded Compounds with Antileukemic Activity.
AID23256Partition coefficient (logP) (hexane)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID1613787Inhibition of PDK in human NCI-H1975 cells assessed as reduction in PDH phosphorylation at 10 mM after 12 hrs by Western blot analysis2019European journal of medicinal chemistry, Feb-15, Volume: 164High-throughput screening of novel pyruvate dehydrogenase kinases inhibitors and biological evaluation of their in vitro and in vivo antiproliferative activity.
AID1170899Increase in oxygen consumption rate in human NCI-H1299 cells at 10 mM incubated for 12 hrs2014Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23
Discovery and optimization of 4,5-diarylisoxazoles as potent dual inhibitors of pyruvate dehydrogenase kinase and heat shock protein 90.
AID1368168Inhibition of PDK1 in human MG63 cells assessed as reduction in pyruvate dehydrogenase complex phosphorylation at ser293 residue at 10 mM after 12 hrs by high content analysis2017Bioorganic & medicinal chemistry letters, 12-15, Volume: 27, Issue:24
Identification of pyruvate dehydrogenase kinase 1 inhibitors with anti-osteosarcoma activity.
AID1613800Antiproliferative activity against human A375 cells assessed as reduction in cell viability after 72 hrs by MTT assay2019European journal of medicinal chemistry, Feb-15, Volume: 164High-throughput screening of novel pyruvate dehydrogenase kinases inhibitors and biological evaluation of their in vitro and in vivo antiproliferative activity.
AID131110In vivo activity in a diabetic mouse at a dose of 1000 umol/kg/day on day1 after 6 hr1999Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15
Triterpene and diterpene inhibitors of pyruvate dehydrogenase kinase (PDK).
AID1271711Induction of apoptosis in human JVM2 cells assessed as late apoptotic cells at 10 mM after 48 hrs by annexin V-FITC/PI-staining based FACS analysis (Rvb = 11%)2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Design, Synthesis, and Biological Characterization of Novel Mitochondria Targeted Dichloroacetate-Loaded Compounds with Antileukemic Activity.
AID1442078Antiproliferative activity against human GM00637 cells after 72 hrs by CCK8 assay
AID23254Partition coefficient (logP) (chloroform)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID1368171Inhibition of PDK1 in human MG63 cells assessed as reduction in pyruvate dehydrogenase complex phosphorylation at ser232 residue at 10 mM after 24 hrs by Western blot analysis2017Bioorganic & medicinal chemistry letters, 12-15, Volume: 27, Issue:24
Identification of pyruvate dehydrogenase kinase 1 inhibitors with anti-osteosarcoma activity.
AID131107In vivo activity in a diabetic mouse at a dose of 1000 umol/kg/day on day 3 after 6 hr1999Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15
Triterpene and diterpene inhibitors of pyruvate dehydrogenase kinase (PDK).
AID131108In vivo activity in a diabetic mouse at a dose of 1000 umol/kg/day on day1 after 2 hours1999Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15
Triterpene and diterpene inhibitors of pyruvate dehydrogenase kinase (PDK).
AID1170897Reduction in extracellular acidification rate in human NCI-H1299 cells at 10 mM incubated for 12 hrs2014Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23
Discovery and optimization of 4,5-diarylisoxazoles as potent dual inhibitors of pyruvate dehydrogenase kinase and heat shock protein 90.
AID23255Partition coefficient (logP) (ether)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID131105In vivo activity in a diabetic mouse at a dose of 1000 umol/kg/day on day 3 after 2 hr1999Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15
Triterpene and diterpene inhibitors of pyruvate dehydrogenase kinase (PDK).
AID1271710Induction of apoptosis in human JVM2 cells assessed as early apoptotic cells at 10 mM after 48 hrs by annexin V-FITC/PI-staining based FACS analysis (Rvb = 1.6%)2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Design, Synthesis, and Biological Characterization of Novel Mitochondria Targeted Dichloroacetate-Loaded Compounds with Antileukemic Activity.
AID1271714Induction of apoptosis in human primary B-CLL cells assessed as early apoptotic cells at 30 mM after 48 hrs by annexin V-FITC/PI-staining based FACS analysis (Rvb = 10.7%)2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Design, Synthesis, and Biological Characterization of Novel Mitochondria Targeted Dichloroacetate-Loaded Compounds with Antileukemic Activity.
AID1442053Inhibition of full length His6-tagged PDK1 (unknown origin) expressed in Escherichia coli using full length His6-tagged PDHA1 as substrate after 30 mins by ELISA
AID1368169Inhibition of PDK1 in human MG63 cells assessed as reduction in pyruvate dehydrogenase complex phosphorylation at ser232 residue at 10 mM after 12 hrs by high content analysis2017Bioorganic & medicinal chemistry letters, 12-15, Volume: 27, Issue:24
Identification of pyruvate dehydrogenase kinase 1 inhibitors with anti-osteosarcoma activity.
AID1442071Inhibition of PDK4 (unknown origin) using full length His6-tagged PDHA1 as substrate after 30 mins by ELISA
AID23253Partition coefficient (logP) (carbon tetrachloride)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID1604107Induction of apoptosis in human H1299 cells assessed as increase in PARP cleavage by Western blot analysis
AID1613796Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay2019European journal of medicinal chemistry, Feb-15, Volume: 164High-throughput screening of novel pyruvate dehydrogenase kinases inhibitors and biological evaluation of their in vitro and in vivo antiproliferative activity.
AID131106In vivo activity in a diabetic mouse at a dose of 1000 umol/kg/day on day 3 after 4 hr1999Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15
Triterpene and diterpene inhibitors of pyruvate dehydrogenase kinase (PDK).
AID1170895Inhibition of PDHK1 in human NCI-H1299 cells assessed as reduction in lactate production at 10 mM incubated for 12 hrs2014Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23
Discovery and optimization of 4,5-diarylisoxazoles as potent dual inhibitors of pyruvate dehydrogenase kinase and heat shock protein 90.
AID23251Partition coefficient (logP)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID1442076Antiproliferative activity against human A549 cells after 72 hrs by CCK8 assay
AID90949In vitro effective concentration in normal human dermal fibroblasts1999Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15
Triterpene and diterpene inhibitors of pyruvate dehydrogenase kinase (PDK).
AID1613799Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay2019European journal of medicinal chemistry, Feb-15, Volume: 164High-throughput screening of novel pyruvate dehydrogenase kinases inhibitors and biological evaluation of their in vitro and in vivo antiproliferative activity.
AID1536195Inhibition of PDK4 in HEK293T cells assessed as reduction in PDHE1alpha phosphorylation at Ser-300 residue by measuring phosphorylated PDHE1alpha level at 5 mM after 24 hrs by Western blot analysis (Rvb = 1 No_unit)2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Discovery of Novel Pyruvate Dehydrogenase Kinase 4 Inhibitors for Potential Oral Treatment of Metabolic Diseases.
AID1613831Inhibition of PDK1 in human NCI-H1975 cells assessed as switch of pyruvate metabolism from lactate production to oxidative phosphorylation by measuring by measuring reduction in lactate formation at 10 mM measured after 4 hrs2019European journal of medicinal chemistry, Feb-15, Volume: 164High-throughput screening of novel pyruvate dehydrogenase kinases inhibitors and biological evaluation of their in vitro and in vivo antiproliferative activity.
AID1817664Inhibition of glycolysis in human A549 cells assessed as reduction in glucose consumption incubated for 8 hrs by colorimetric-oxidase mediator analysis2021Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14
Carbohydrate-Based NK1R Antagonists with Broad-Spectrum Anticancer Activity.
AID1402795Inhibition of PDK1 in human HeLa cells assessed as decrease in PDH-E1 alpha p-ser232 expression at 10 mM by Western blot analysis2018European journal of medicinal chemistry, Jan-20, Volume: 144Design and characterization of α-lipoic acyl shikonin ester twin drugs as tubulin and PDK1 dual inhibitors.
AID1604104Induction of apoptosis in human DU145 cells assessed as increase in apoptotic cells at 30 uM incubated for 48 hrs by FITC Annexin-V and PI staining based flow cytometric analysis relative to control
AID384212Mutagenic activity in Salmonella Typhimurium TA100 assessed as logarithm of his+ revertant number increasing activity by amens test2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
Halogenated derivatives QSAR model using spectral moments to predict haloacetic acids (HAA) mutagenicity.
AID1271716Upregulation of p21 mRNA expression in human primary B-CLL cells at 300 uM after 24 to 48 hrs by qRT-PCR analysis2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Design, Synthesis, and Biological Characterization of Novel Mitochondria Targeted Dichloroacetate-Loaded Compounds with Antileukemic Activity.
AID1613785Inhibition of porcine PDK assessed as activation of pyruvate dehydrogenase complex measured after 3 mins2019European journal of medicinal chemistry, Feb-15, Volume: 164High-throughput screening of novel pyruvate dehydrogenase kinases inhibitors and biological evaluation of their in vitro and in vivo antiproliferative activity.
AID1271717Induction of p21 protein level in human primary B-CLL cells at 300 uM after 24 to 48 hrs by Western blot analysis2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Design, Synthesis, and Biological Characterization of Novel Mitochondria Targeted Dichloroacetate-Loaded Compounds with Antileukemic Activity.
AID1536194Inhibition of PDK4 in HEK293T cells assessed as reduction in PDHE1alpha phosphorylation at Ser-293 residue by measuring phosphorylated PDHE1alpha level at 5 mM after 24 hrs by Western blot analysis (Rvb = 1 No_unit)2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Discovery of Novel Pyruvate Dehydrogenase Kinase 4 Inhibitors for Potential Oral Treatment of Metabolic Diseases.
AID1271707Cytotoxicity against human MEC2 cells after 48 hrs by MTT assay2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Design, Synthesis, and Biological Characterization of Novel Mitochondria Targeted Dichloroacetate-Loaded Compounds with Antileukemic Activity.
AID1613801Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay2019European journal of medicinal chemistry, Feb-15, Volume: 164High-throughput screening of novel pyruvate dehydrogenase kinases inhibitors and biological evaluation of their in vitro and in vivo antiproliferative activity.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID23252Partition coefficient (logP) (benzene)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID1271695Cytotoxicity against human Maver1 cells after 48 hrs by MTT assay2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Design, Synthesis, and Biological Characterization of Novel Mitochondria Targeted Dichloroacetate-Loaded Compounds with Antileukemic Activity.
AID1613789Inhibition of PDK in human NCI-H1975 cells assessed as reduction in PDH phosphorylation at Ser293 residue at 10 mM by ELISA2019European journal of medicinal chemistry, Feb-15, Volume: 164High-throughput screening of novel pyruvate dehydrogenase kinases inhibitors and biological evaluation of their in vitro and in vivo antiproliferative activity.
AID1402705Antiproliferative activity against human MDA231 cells after 24 hrs by MTT assay2018European journal of medicinal chemistry, Jan-20, Volume: 144Design and characterization of α-lipoic acyl shikonin ester twin drugs as tubulin and PDK1 dual inhibitors.
AID162967In vitro inhibitory activity against pyruvate dehydrogenase kinase was determined1999Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15
Triterpene and diterpene inhibitors of pyruvate dehydrogenase kinase (PDK).
AID1402793Inhibition of PDK1 in human HeLa cells assessed as increase in PDH-E1 alpha expression at 10 mM by Western blot analysis2018European journal of medicinal chemistry, Jan-20, Volume: 144Design and characterization of α-lipoic acyl shikonin ester twin drugs as tubulin and PDK1 dual inhibitors.
AID1442055Inhibition of PDK2 (unknown origin) using full length His6-tagged PDHA1 as substrate after 30 mins by ELISA
AID1442069Inhibition of full length His6-tagged PDK1 (unknown origin) expressed in Escherichia coli using full length His6-tagged PDHA1 as substrate in presence of GSH after 30 mins by ELISA
AID1802790PDK Inhibition Assay from Article 10.1074/jbc.M113.533885: \\Structure-guided development of specific pyruvate dehydrogenase kinase inhibitors targeting the ATP-binding pocket.\\2014The Journal of biological chemistry, Feb-14, Volume: 289, Issue:7
Structure-guided development of specific pyruvate dehydrogenase kinase inhibitors targeting the ATP-binding pocket.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,210)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990224 (18.51)18.7374
1990's289 (23.88)18.2507
2000's247 (20.41)29.6817
2010's360 (29.75)24.3611
2020's90 (7.44)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 66.17

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index66.17 (24.57)
Research Supply Index7.18 (2.92)
Research Growth Index4.69 (4.65)
Search Engine Demand Index118.69 (26.88)
Search Engine Supply Index2.06 (0.95)

This Compound (66.17)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials56 (4.48%)5.53%
Reviews79 (6.32%)6.00%
Case Studies57 (4.56%)4.05%
Observational0 (0.00%)0.25%
Other1,058 (84.64%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]